Seminal Plasma Promotes Lesion Development in a Xenograft Model of Endometriosis

Jonathan T. McGuane,* Katherine M. Watson,* Jamie Zhang,* M. Zahied Johan,* Zhao Wang,* Gabriel Kuo,* David J. Sharkey,* Sarah A. Robertson,* and M. Louise Hull*

From the Robinson Research Institute and Discipline of Obstetrics and Gynaecology,* School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, South Australia; the Department of Obstetrics and Gynaecology,1 Women’s and Children’s Hospital, North Adelaide, Adelaide, South Australia; and the Fertility SA IVF Unit,1 Adelaide, South Australia, Australia

The factors that predispose one-tenth of reproductive-aged women to endometriosis are poorly understood. We determined that genetic deficiency in transforming growth factor b1 impairs endometriosis-like lesion growth in mice. Given that seminal plasma is an abundant source of transforming growth factor b, we evaluated the effect of exposure to seminal plasma on the growth of endometrial lesions. Human endometrial explants were exposed to seminal plasma or to control medium before transfer to Prkdcscid mutant (severe combined immunodeficient) mice. Xenografts exposed to seminal plasma showed an eightfold increase in volume and a 4.3-fold increase in weight after 14 days. These increases were associated with increased proliferation of endometrial epithelial cells and enhanced survival and proliferation of human stromal cells compared with those in control lesions, in which human stromal cell persistence was negligible. Although the distribution of macrophages was altered, their number and activation status did not change in response to seminal plasma. Seminal plasma stimulated the production of a variety of cytokines in endometrial tissue, including growth-regulated oncogene, granulocyte macrophage colony-stimulating factor, and IL-1b. These data suggest that seminal plasma enhances the formation of endometriosis-like lesion via a direct effect on endometrial cell survival and proliferation, rather than via macrophage-mediated mechanisms. These findings raise the possibility that endometrial exposure to seminal plasma could contribute to endometriotic disease progression in women.

(Am J Pathol 2015, 185: 1409–1422; http://dx.doi.org/10.1016/j.ajpath.2015.01.010)
Transforming growth factor (TGF)-β1 is a multifunctional cytokine that is elevated in endometriotic lesions, serum, and peritoneal fluid in women with endometriosis.\textsuperscript{11–13} When human tissue fragments were transferred to immunocompromised mice with a null mutation in Tgfb1, smaller ectopic endometriosis-like lesions developed compared with those in wild-type controls, showing that TGF-β1 bioavailability is a key determinant of lesion growth.\textsuperscript{14}

Seminal plasma, the acellular fraction of seminal fluid, contains several cytokines, including very high concentrations of TGF-β1, TGF-β2, and TGF-β3.\textsuperscript{15} Seminal plasma injected i.p. increased cellular proliferation, angiogenesis, and tissue remodeling when human cervical adenocarcinoma cells were injected s.c. into nude mice.\textsuperscript{16} In vitro experiments have demonstrated increased proliferation of human endometrial epithelial cells after the addition of seminal plasma to culture media.\textsuperscript{17,18} This finding suggests the possibility that in women, seminal plasma exposure might enhance epithelial cell proliferation in retrograde menstrual endometrium, contributing to the development or progression of endometriosis.

Histological analysis indicates that endometriosis-like lesions progress from an acute inflammatory state, with neutrophil and early macrophage infiltration, to a healing and remodeling phenotype, in which macrophage and myofibroblast activity predominates.\textsuperscript{19} In an acute inflammatory response, phagocytic macrophages display classic (M1) activation markers such as C-C chemokine receptor (CCR)-7 and produce factors such as nitric oxide (iNOS).\textsuperscript{20} To prevent uncontrolled classic activation, phagocytic tags from dying cells alternatively activate macrophages via enhanced TGF-β signaling.\textsuperscript{21} These M2 macrophages display the alternative activation marker macrophage mannose receptor (MMR/CD206), scavenge cellular debris, and promote tissue remodeling, angiogenesis, and repair.\textsuperscript{20}

In a mouse model, M2 macrophage activity promoted, and M1 macrophage activity suppressed, endometriosis-like lesion development.\textsuperscript{22} Additionally, in TGF-β1−deficient mice, fewer macrophages were identified in ectopic endometrial lesions, suggesting that altered macrophage activity may have contributed to lesion repression. The high levels of TGF-β1 in seminal plasma could enhance lesion development by promoting an M2 macrophage healing response in ectopic endometrial tissues.

In cervical and endometrial tissues exposed to seminal plasma, TGF-β1 activates the heterotetrameric TGF-βR1/TGF-βR2 receptor complex, leading to the up-regulation of several cytokines and chemokines, including granulocyte macrophage (GM) colony-stimulating factor (CSF), IL-1β, IL-6, IL-8, monocyte chemotactic protein 1, macrophage inflammatory protein 1α, and leukemia inhibitory factor.\textsuperscript{23–25} These cytokines and chemokines recruit endometrial macrophages and dendritic cells to activate regulatory T cells and create a tolerogenic environment for an implanting embryo.\textsuperscript{19} Thus, it is plausible that seminal plasma−exposed endometrial tissue in retrograde menstrual fluid is more likely to escape immune surveillance, attach, and proliferate at an ectopic site in response to these chemokines.

We hypothesized that exposure to seminal plasma enhances the development of endometriotic lesions via either a direct proliferative effect on endometrial cells or by increased M2 macrophage−directed healing and repair. Additionally, we hypothesized that alterations in endometrial cytokine profile induced by seminal plasma underpin these effects. A xenograft mouse model was used to test the effect of direct endometrial exposure to seminal plasma on endometriosis-like lesion growth in vivo. Immunohistochemistry (IHC) analysis was used for quantifying the effect of seminal plasma on the cellular composition and activation status of macrophages in human endometrial explants and xenografts recovered from immunocompromised mice. Finally, we explored seminal plasma−induced cytokine mediators that may influence endometriotic lesion development in human endometrial explant cultures.

### Materials and Methods

#### Ethics Approval

Approval for the use of human seminal plasma was obtained from the human ethics committees of St. Andrew’s Hospital (Adelaide, SA, Australia), the University of Adelaide (Adelaide, SA, Australia), and the North Western Adelaide Health Service (Adelaide, SA, Australia) (REC 1394/03/08). The use of human endometrial tissue was approved by the human ethics committees of the Children, Youth and Women’s Health Service (Adelaide, SA, Australia) (REC 2280/5/13). Animal experiments were approved by the animal ethics committees of the University of Adelaide (M-2012-080) and the Children, Youth and Women’s Health Service (AE 838/4/14), and conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.\textsuperscript{26}

#### Seminal Plasma Collection

Human seminal plasma was obtained from the male partners, aged 36 to 52 years (n = 6), of women undergoing treatment for female-factor infertility at Fertility SA (St. Andrew’s Hospital) and healthy-proven fertile men (n = 4). Sperm analysis was conducted according to the recommendations of the World Health Organization, and samples were included only if all parameters were consistent with normal values in the World Health Organization Laboratory Manual for the Examination and Processing of Human Semen.\textsuperscript{27} None of the samples displayed leukospermia or were obtained from men taking immune-deviating drugs. After liquefaction, each sample was centrifuged at 10,000 × g for 10 minutes at room temperature within 1 hour of ejaculation. The seminal plasma supernatant was then aspirated and frozen at −80°C. Equal portions of seminal plasma were subsequently thawed and pooled (to minimize the effect of variation in cytokine levels between individuals\textsuperscript{25}), aliquoted, and stored at −80°C. Our
previous experience indicates that seminal plasma prepared in this way retains full bioactivity (unpublished data).

Collection of Human Endometrial Tissue

Endometrial biopsy samples (n = 4) of normal histological appearance appropriate for cycle phase were collected from women aged 36 to 40 years using Pipelle suction curettage (Pipelle de Cornier, Laboratoire C.C.D., Paris, France) during diagnostic laparoscopy for infertility. Exclusion criteria included the use of hormonal contraceptives in the 3 months before surgery, or surgery for gynecological cancer. No participant had endometriosis; two were in the proliferative phase and two were in the secretory phase of the cycle. Previous work suggests cycle phase has little impact on the growth of the resulting endometriosis-like lesions (unpublished data). A separate series of endometrial biopsies was collected from five women in the secretory phase for studies of macrophage phenotype. These patients were undergoing hysterectomy and endometrial biopsy and their endometriosis status was not determined; however, all were asymptomatic.

The tissue was placed in phenol red–free Dulbecco’s modified Eagle’s medium:F12 (Sigma-Aldrich, Castle Hill, NSW, Australia) with 1% each insulin-transferrin-selenium-X supplement and penicillin/streptomycin (both, Life Technologies, Mulgrave, VIC, Australia), 0.1% Ex-Cyte (Merck Millipore, Kilisly, VIC, Australia), and 10 nmol/L 17β-estradiol (Sigma-Aldrich) as previously described.14 Tissues were cut into approximately 1 mm³ fragments, placed into multiwell plates (15 fragments/well), and incubated for 24 hours in media (Sigma-Aldrich) as previously described.14 Tissues were cut into approximately 1 mm³ fragments, placed into multiwell plates (15 fragments/well), and incubated for 24 hours in media alone or in media containing 10% seminal plasma.

Mice

Female mice homozygous for the Prkdcscid mutation (severe combined immunodeficiency) were purchased from Laboratory Animal Services (University of Adelaide) at 5 weeks of age. Mice were housed under controlled light conditions (12-hour light:dark cycle) with ad libitum access to a standard diet and sterilized water. At 6 weeks of age, mice were anesthetized with 1.5% isoFlurane (Veterinary Companies of Australia, Artarmon, NSW, Australia) and bilaterally ovariectomized via a single mid-dorsal incision. A 60-day release 1.5 mg 17β-estradiol pellet (Innovative Research, Sarasota, FL) was placed s.c. in the left flank via the same incision. Mepipvaine (0.02%; Ceva Animal Health, Glenorrie, NSW, Australia) was administered at the incision site immediately after surgery. Buprenorphine (16 mg/mL; Reckitt Benckiser, West Ryde, NSW, Australia) was given at 0.05 mL per 10 g body weight for 12 hours postoperatively for further analgesia as needed.

One to two weeks after ovariectomy, mice were anesthetized using isoflurane, and endometrial fragments were injected s.c. ventrally. Mice were randomly allocated to receive human endometrial tissue that had been incubated with 10% seminal plasma for 24 hours (n = 10 mice) or control human endometrial tissue that had been incubated in media only for 24 hours (n = 11 mice). Preliminary studies of cytokine responses indicated that these conditions were optimal (data not shown), consistent with previous in vitro work.28,29 The seminal plasma concentration used represents an estimate of the highest possible physiologically relevant concentration in the uterus. Each mouse received 15 tissue fragments (i.e., the tissue contents of 1 seminal plasma—treated or control culture well) from one patient as previously described.30 The number of mice receiving transplanted tissue from a single donor varied depending on the size of the biopsy sample, but each biopsy sample was distributed approximately equally between the groups.

Fourteen days post–endometrial tissue injection, mice were administered 100 μL of 10 mg/mL 5-bromo-2′-deoxyuridine (BrdU) and 5-fluoro-2′-deoxyuridine mixture (Sigma-Aldrich) i.p. and euthanized 1 hour later with 400 μL 2,2,2-tribromoethanol (Sigma-Aldrich) i.p. Endometriosis-like lesions were measured (length × width × depth) using calipers, then dissected, removed, and weighed in a blinded fashion (K.M.W.) (Figure 1A). Tissues were transferred to 4% paraformaldehyde for 24 hours, followed by washing in phosphate-buffered saline and immersion in 70% ethanol. Tissues were dehydrated in an ascending ethanol series and transferred to xylene, then embedded in paraffin before sectioning at 5 μm.

In Vitro Experiments

 Portions of the same endometrial biopsies obtained for in vivo studies were used for analyzing cytokine production in response to seminal plasma. The additional endometrial tissues collected were prepared in triplicate for the study of macrophage phenotype in explant culture. In both experiments, an equal number of tissue fragments (1 mm³) were treated in NunccloneΔ Surface multiwell plates (Thermo Scientific, Scoresby, VIC, Australia) with media containing 10% seminal plasma or media alone. Additional control wells for cytokine studies contained media with 10% seminal plasma but no tissue. Explants were incubated for 24 hours under standard cell culture conditions before conditioned media were collected for multiplex cytokine analysis and tissue was transferred to RNAlater (Sigma-Aldrich) for quantitative real-time RT-PCR or 4% paraformaldehyde for IHC analysis.

IHC and Morphometric Analysis of Endometriosis-Like Lesions and Endometrial Explants

Hematoxylin and eosin (Sigma-Aldrich) staining was performed on every 20th section from endometriosis-like lesions; one lesion from the control group was found not to contain glandular epithelium and was excluded from IHC analysis. The BrdU In-Situ Detection Kit (BD, North Ryde, NSW, Australia) was used to detect proliferating cells in endometriosis-like lesions as per the manufacturer’s instructions. Mouse anti-human leukocyte antigen class 1 (HLA-1) (1:200 dilution; Abcam, Melbourne, VIC, Australia) was used for distinguishing human
and mouse tissue in xenografts. The antibody clone used (EMR8-5) recognizes a nonpolymorphic determinant present on all HLA-1 heavy chains (ie, A, B, and C). Additional sections were stained with rat anti-mouse F4/80 IgG2a (1:800 dilution; eBioscience, San Diego, CA), mouse anti-α-smooth muscle actin IgG2a (1:500; Sigma-Aldrich), or rabbit anti-von Willebrand factor polyclonal antibodies (1:600; Merck Millipore, Macquarie Park, NSW, Australia) to identify macrophages (murine), myofibroblasts, and endothelial cells, respectively. Sections from both endometriosis-like lesions and endometrial explants were stained with mouse anti-human CD68 (1:50 dilution; Dako, Campbellfield, VIC, Australia), mouse anti-GM-CSF, granulocyte macrophage colony-stimulating factor; GR0, growth-regulated oncogene; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein.

Morphometric analyses were performed by an assessor (J.Z. or J.T.M.) blinded to treatment group. Sections were imaged coverslips were applied. After washing, biotinylated

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
<th>Concentration (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF2 (GM-CSF)</td>
<td>5'-AGCTCAGACGTGCTCTACTC-3'</td>
<td>5'-CATCTCAGAGTGCTCTACTC-3'</td>
<td>0.5</td>
</tr>
<tr>
<td>IL10</td>
<td>5'-GCGAGCTGCTGACACCTTCA-3'</td>
<td>5'-CCACCGCCTTGCTTTGTT-3'</td>
<td>0.25</td>
</tr>
<tr>
<td>CXCL1 (GR0a)</td>
<td>5'-CCACCTGCGCCCAACC-3'</td>
<td>5'-GCAGGATTAGGCGAACTTTT-3'</td>
<td>0.5</td>
</tr>
<tr>
<td>CCL22 (MDC)</td>
<td>5'-GCTGTTGTGTTAAAAACCTTCC-3'</td>
<td>5'-ACTCTGGGATCGGACCAGAT-3'</td>
<td>0.25</td>
</tr>
<tr>
<td>IL1B</td>
<td>5'-CCTGAGCTCACCAGTGA-3'</td>
<td>5'-TTTAGGGCCCTATCGCCTCAA-3'</td>
<td>0.25</td>
</tr>
<tr>
<td>CCL4 (MIP-1β)</td>
<td>5'-AGCGCTCTCAGCACCATTG-3'</td>
<td>5'-CTTCCCTGCGGTGTAGAAA-3'</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Protein names that differ from the gene names are shown in parentheses.

GM-CSF, granulocyte macrophage colony-stimulating factor; GR0, growth-regulated oncogene; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein.

Using a NanoZoomer (Hamamatsu Photonics, Hamamatsu, Japan). The proportion of BrdU-positive cells was calculated by manual counting in ImageJ software version 1.48 (NIH, Bethesda, MD) of at least 1300 cells in at least three fields per lesion. HLA-1-positive and macrophage-free stromal area was determined by measuring the glands (epithelium and lumen) and the subepithelial portion of stroma containing/devoid of substantial staining, respectively, and expressed as a percentage of the total area of each section (NanoZoomer Viewer, Hamamatsu Photonics). F4/80, von Willebrand factor, and α-smooth muscle actin staining in endometriosis-like lesions was analyzed in up to 10 fields using VideoPro 32 software version 2.1 (Leading Edge, Adelaide, SA, Australia) and expressed as percentage of positive area. CD68, CD206, CCR7, and iNOS were similarly measured in multiple fields encompassing the entire endometrial explant tissue section.

Multiplex Cytokine Analysis of Conditioned Media

A custom Milliplex MAP Human Cytokine/Chemokine 96-well multiplex assay (Merck Millipore) was designed and run on a Luminex 200 System (Luminex Corp., Austin, TX) according to the manufacturer’s instructions. The minimal detectable limits of the 20 analytes ranged from 0.4 to 26.3 pg/mL. A separate assay (R&D Systems) was used for assessing IL-4 and macrophage CSF levels in conditioned media. Samples that were below the minimal detectable limits were excluded; only analytes for which >50% of samples tested were above the minimal detectable limits were considered for statistical analysis. The mean intra- and interassay coefficients of variation for each analyte were 13% and 5%, respectively.

Quantitative Real-Time RT-PCR Analysis of Seminal Plasma—Treated Explants

Total RNA was extracted from seminal plasma—treated and control explants using TRIzol reagent (Life Technologies) with RNeasy column purification (Qiagen, Chadstone, VIC, Australia) as per the manufacturer’s instructions. Spectrophotometric analysis on a NanoDrop ND-1000 (Thermo Scientific) confirmed the purity of the resultant sample
Total RNA (60 ng) was reverse-transcribed in a volume of 20 μL using SuperScript III with 250 ng random primers (both, Life Technologies) as per the manufacturer’s instructions. PCR was performed in triplicate for ACTB and in duplicate for cytokine genes using Power SYBR Green Master Mix on an Applied Biosystems 7900HT Real-Time PCR system (both, Life Technologies). Cytokine gene fold-change in response to treatment with seminal plasma was calculated using the ΔΔCt method. The primer sequences used are listed in Table 1. Primer concentration was optimized in pilot studies, and dissociation curve analysis confirmed the absence of dimer formation for each pair. Ct values for the endogenous control gene did not differ significantly between the groups [control, 24.1 ± 1.0; 10% seminal plasma, 25.0 ± 1.9 (means ± SEM)]. The coefficient of variation for replicate PCR wells was 1.25% ± 0.4% (means ± SEM of cytokine genes).

**Statistical Analysis**

All analyses of endometriosis-like lesions and endometrial explants were performed using the U-test or Wilcoxon signed rank test for independent or related samples, respectively, as appropriate. For *in vivo* data, analyses were performed on values for individual mice. Cytokine concentration in conditioned media from human endometrial explants was analyzed by 1-way analysis of variance and Fisher’s least significant difference post hoc tests after passing the Shapiro-Wilk test for normality. Fold-change cytokine mRNA levels were analyzed by 1-sample *t*-test. Correlation between morphometric variables was assessed using the Pearson coefficient. The software programs used were GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA), SAS version 9.3 (SAS Institute, Cary, NC), and SPSS Statistics version 20 (IBM, Armonk, NY).

**Results**

**Seminal Plasma Exposure Enhances the Size and Weight of Endometriosis-Like Lesions**

Initially, to test the effect of seminal plasma on the development of endometriosis-like lesion, we used the SCID mouse model of endometriosis and exposed tissues to human seminal plasma before transfer to recipient mice. On day 14 after transfer, SCID mouse xenografts originating from seminal plasma–exposed endometrium were found to be significantly larger (*P* < 0.015) and heavier (*P* < 0.026) than lesions originating from tissue exposed to culture medium alone (Figure 1, B and C). There was no significant effect of treatment on the proportion of mice that developed endometriosis-like lesions (6 of 10 mice in the seminal plasma exposure group and 6 of 11 control mice).

**Seminal Plasma Expands the Donor Tissue Compartment and Promotes Epithelial Proliferation in Endometriosis-Like Lesions**

Hematoxylin and eosin analysis did not reveal any difference in the fractional area of glands or stroma in endometriosis-like lesions exposed to seminal plasma (*P* = 0.309). However, lesions may contain both donor human and host mouse tissue, and hematoxylin and eosin staining does not distinguish between these. We thus examined the relative...
proportion of human and murine tissue in lesions using an antibody to HLA-1, which is exclusively expressed by human cells. There was a significantly greater proportion of donor tissue in endometriosis-like lesions from the seminal plasma group ($P = 0.016$) (Figure 2A and C). Large areas of human stromal tissue were identified surrounding the human-derived glandular epithelium in lesions that had been exposed to seminal plasma. In contrast, human stromal tissue was rarely detected in control lesions, and only the glandular epithelium expressed HLA-1.

We hypothesized that enhanced cellular proliferation in the human tissue compartment may have accounted for this increased tissue area. When proliferating cells were quantified, BrdU-positive epithelial cells were significantly more numerous in endometriosis-like lesions after seminal plasma treatment compared with controls ($P = 0.038$) (Figure 2B and D). There was no difference between the groups in the number of BrdU-positive cells in the stroma when mouse and human tissue were considered as a whole. Substantial proliferation was also observed in the human stromal tissue of the lesions exposed to seminal plasma, but since this compartment was effectively absent from control lesions, no stromal cell proliferation was detected in those tissues (Figure 2E). Within seminal plasma–treated lesions, the concentration of proliferating cells was significantly greater in the human compared with the murine stromal tissue compartment ($P = 0.046$) (Supplemental Figure S1).

Seminal Plasma Alters Macrophage Distribution in Endometriosis-Like Lesions

Measurement of F4/80 staining revealed no difference in the density of mouse macrophages in lesions from the two groups. However, the spatial distribution was altered in lesions exposed to seminal plasma such that there was a larger area of stromal tissue subjacent to the epithelium where host mouse macrophages failed to infiltrate (Figure 3A). In contrast, macrophages were observed in close proximity to the glandular epithelium in lesions from the control group (Figure 3A). The difference in the
proportion of macrophage-free stroma was statistically significant ($P = 0.016$), with a pattern of distribution inverse to that of HLA-1. There was a significant correlation between macrophage-free stromal and HLA-1-positive area ($r = 0.91; P = 0.00006$). Tissue controls confirmed that the F4/80 antibody used is specific to mouse macrophages and does not react with human endometrium, whereas HLA-1 was detected in human endometrium but not in murine tissues (Supplemental Figure S2).

Analysis of von Willebrand factor staining indicated no difference in blood vessel density after exposure to seminal plasma (Figure 3B). Like mouse macrophages, myofibroblasts were routinely observed subjacent to the epithelial layer in control lesions, but myofibroblasts in this location were rare in seminal plasma—exposed lesions (Figure 3C). There was a trend toward reduced myofibroblast density, as measured by $\alpha$-smooth muscle actin staining in seminal plasma—exposed lesions ($P = 0.056$). There were no differences in von Willebrand factor or $\alpha$-smooth muscle actin staining between the human and mouse compartments of seminal plasma—exposed lesions.

Seminal Plasma Does Not Change Macrophage Phenotype or Number in Endometriosis-Like Lesions or Explants

As the distribution of mouse macrophages was altered in seminal plasma—exposed endometriosis-like lesions, we sought to characterize the macrophages present. Using the human macrophage marker CD68, we observed that in contrast to naïve endometrial tissue (which is replete with macrophages), endometriosis-like lesions from both the seminal plasma—treated and control groups contained only sporadic CD68-positive cells (Figure 4A).

To determine whether macrophages displaying markers of alternate (M2) or acute (M1) activation were present in endometriosis-like lesions, IHC quantification of MMR/CD206, CCR7, and iNOS was undertaken. MMR-positive cells (M2 macrophages) displayed a similar pattern to that of $\alpha$-SMA (% positive area)

**Figure 3** Effects of exposure to seminal plasma on mouse macrophage distribution and endothelial cell and fibroblast density in endometriosis-like lesions. Representative images of sections from seminal plasma (SP)-treated (left) and control tissues (center) stained for F4/80 (A), von Willebrand factor (vWF) (B), and $\alpha$-smooth muscle actin ($\alpha$-SMA) (C). Dotted lines (A) delineate F4/80-positive (F4/80+) tissue boundaries. Insets, B and C: Isotype-matched antibody negative controls. The proportions of subepithelial stromal tissue principally devoid of macrophages (graphs, A) and the percentage of area of tissue stained for vWF (graphs, B) or $\alpha$-SMA (graphs, C). Boxes represent the medians and interquartile ranges; whiskers represent minimal and maximal values. $n = 6$ and 4 mice in the SP and control groups, respectively, because in one control lesion glandular material was insufficient for quantification. *$P < 0.05$ (U-test). Scale bars: 500 μm (seminal plasma) or 250 μm (control) (A); 100 μm (B and C).
F4/80 staining and were detected in the murine but not in the human compartment of endometriosis-like lesions (Figure 4B). There was no difference in MMR-positive macrophage density between the groups. Tissue controls confirmed that the CD68 antibody detects only human macrophages (Figure 4C), whereas the MMR antibody detects M2 macrophages of both human and mouse origin (Figure 4D). There were few or no CCR7- or iNOS-positive cells (M1 macrophages) in either seminal plasma-treated or control lesions.

To evaluate whether seminal plasma exposure skewed markers of macrophage activation earlier in the time course of lesion development, endometrial explants were examined immediately after exposure to seminal plasma in vitro. Macrophages as defined by CD68 immunoreactivity were abundant in seminal plasma—treated and control tissue after 24 hours in culture (Figure 5A). As in endometriosis-like lesions, M2 (MMR-positive) macrophages were readily detected (Figure 5B), whereas endometrial explants were relatively devoid of M1 (CCR7-/iNOS-positive) macrophages (Figure 5, C and D). Seminal plasma did not alter the density of CD68-, MMR-, CCR7-, or iNOS-positive cells (Figure 5E). Breast cancer control sections confirmed that CCR7 and iNOS proteins were detectable with the IHC procedure used (Supplemental Figure S3).

Seminal Plasma Modulates Cytokine Profile in Human Endometrial Explants

To investigate the mechanism by which seminal plasma exerts biological effects in endometrial tissue, cytokine production and mRNA expression were evaluated in response to seminal plasma exposure. In vitro treatment with 10% seminal plasma for 24 hours resulted in significantly higher concentrations of macrophage inflammatory protein 1β, GM-CSF, IL-1β, macrophage-derived chemokine, IL-10, and growth-regulated oncogene (GRO) in conditioned media of tissues treated with seminal plasma compared with those in seminal plasma alone or tissue alone (all, $P < 0.05$ by 1-way analysis of variance) (Figure 6A), and a seminal plasma—induced increase in IL-8 was of borderline significance ($P = 0.051$) (Supplemental Figure S4). Levels of macrophage CSF, granulocyte CSF, IL-1α, IL-6, interferon γ—inducible protein 10, monocyte
chemotactic proteins 1 and 3, regulated on activation normal T cell expressed and secreted, tumor necrosis factor-α, and vascular endothelial growth factor A were not different between the treatment groups, although tissue incubated with seminal plasma produced the numerically highest concentration in each case (Supplemental Figure S4). IL-4, eotaxin, fractalkine, IL-1RA, and macrophage inflammatory protein 1α were undetectable in ≥50% of the explants tested.

At the mRNA level, there was a trend toward increased transcript abundance for each of the cytokines that were elevated in conditioned media after seminal plasma exposure (Figure 6B). This finding was most pronounced for IL-1β (fold-change, 4.43 ± 1.86). Statistical significance was not reached, partly due to considerable patient-to-patient variability.

**Discussion**

This is the first study to demonstrate an association between contact with seminal plasma and the development of endometriosis in an in vivo model. Direct endometrial exposure to seminal plasma was associated with consistent and substantial increases in the volume and weight of resultant endometriosis-like lesions. Morphometric analysis of the lesions demonstrated an increased proportion of tissue immunopositive for HLA-1, a substantial impact on the persistence of the human endometrial stromal compartment, and increased endometrial epithelial cell proliferation. These findings indicate an increased propensity of human endometrial tissue to survive and proliferate at an ectopic site after contact with seminal plasma.

Few macrophages were seen in the large areas of retained human stroma surrounding the glands in seminal plasma-exposed lesions. Moreover, differences in total macrophage density or macrophage activation status were not detected in xenografts or in human endometrial tissue explants exposed to seminal plasma in vitro. Thus the endometrial cytokine response to seminal plasma appears predominantly to directly support the proliferation of epithelial cells and the survival of stromal cells of endometrial origin, rather than the induction of alterations in macrophage activity and function to promote endometriosis-like lesion development.

**Rationale and Study Limitations**

The SCID mouse model of endometriosis used in this study offers the advantage of in vivo functional assessment of human endometrial tissues, which is not possible in syngeneic mouse models or in clinical trials in women. Although macrophage activity and innate immune responses are intact in SCID mice, humoral T- and B-cell activity is absent, which is a limitation in its representation of human disease. Although our findings suggest that retrograde-shed endometrium exposed to seminal plasma in vivo could have a higher propensity for proliferation and growth at an ectopic site in women, additional clinical studies are required for validation of this theory. There is some epidemiological evidence to support this premise, as endometriosis is more common in women who report coitus during menses compared with patients who avoid intercourse at that time.31

Postcoitally, the cervix encounters seminal plasma at moderate to high concentrations; however, the extent to which seminal plasma contacts the endometrium after intercourse is difficult to measure in women and remains a point of contention. Uterine insuck of seminal fluid has been proposed as a
physiological possibility,\textsuperscript{32–34} and several studies have demonstrated that technetium-labeled albumin macroscopically placed at the external os of the cervix reach the tubes within 1 minute as a result of subendometrial and myometrial peristaltic activity.\textsuperscript{35,36} Uterine contraction induced by menstruation \textsuperscript{33} and coitus may increase vagina-to-uterus transport, thus exposing intact and shedding endometrium to higher seminal plasma concentrations and could enhance retrograde flow of endometrial debris into the peritoneal cavity. Other mechanisms, including binding of TGF-\(\beta\) and other active seminal constituents to the postacrosomal region of the sperm head,\textsuperscript{37} provide further support for the concept of a physiologically relevant interaction between endometrium and seminal plasma constituents.

Direct Effect of Seminal Plasma on Endometrial Tissue

Increased proliferation of endometrial epithelial cells was seen in xenografts derived from endometrial tissue exposed to seminal plasma. Enhanced proliferation after exposure to seminal plasma was previously demonstrated in endometrial epithelial cell cultures and in a xenograft model of endometriosis-like lesions, consistent with our findings. Here, persistence of human donor stromal cells was identified only in endometriosis-like lesions exposed to seminal plasma, suggesting that direct exposure induces survival and proliferation of both the stromal and the epithelial compartments of human endometrium. The surrounding murine stromal tissues did not demonstrate differences in cellular proliferation. This finding indicates that seminal plasma-induced changes in the tissue exert a predominantly local effect on human endometrial cells. Although we did not detect any changes in mouse macrophages or other overt aspects of the host compartment that would suggest an indirect effect of seminal plasma, we cannot exclude effects in host immune or other cells.

Lack of Host Macrophage, Myofibroblast, and Vascular Cell Response

Cytokines produced by endometrial tissue in response to seminal plasma are likely to induce recruitment and activation of immune cells,\textsuperscript{33,34} which could in turn contribute to the establishment and/or growth of xenografts. However, the numbers of macrophages and myofibroblasts in endometriosis-like lesions were not altered by seminal plasma exposure. This finding was unexpected, as lower numbers of both cell types were identified in association with smaller lesions in the host TGF-\(\beta\)-deficient mouse model of endometriosis,\textsuperscript{14} and seminal plasma is an abundant source of TGF-\(\beta\) that induces profound leukocyte recruitment in the female reproductive tract after coitus.\textsuperscript{24,38} This difference between the effect of seminal plasma and TGF-\(\beta\)-1 manipulation could relate to the presence of other bioactive moieties in seminal plasma, including prostaglandin E or various steroid hormones (eg, estrogen).\textsuperscript{39,40}

In xenografts exposed to seminal plasma, the distribution of macrophages was altered, with few macrophages (human or murine) in the abundant human endometrial stromal tissue surrounding endometrial glandular epithelial cells. We explored the macrophage activation status in xenografts and in tissue explants exposed to seminal plasma \textit{in vitro}. In both experiments, the M2 macrophage marker iNOS was relatively prevalent, but seminal plasma exposure did not appear to alter its expression. The M1 markers iNOS and CCR7 demonstrated very low abundance, providing evidence that in endometrial explants \textit{in vitro} and in endometriosis-like

![Figure 6](https://example.com/f6.png)
xenografts, the reparative environment associated with alternate M2 macrophage activity prevails. This environment was previously shown to enhance ectopic endometrial lesion development in a mouse model.22

We did not detect differences in blood vessel density between endometriosis-like lesions after seminal plasma exposure. A previous study attributed the enhanced development of s.c. HeLa tumor cell xenografts in response to seminal plasma to increased delivery of nutrients and oxygen via an enhanced vascular supply.16 Consistent with our result, there was no effect of seminal plasma on vascular epithelial growth factor production in vitro. The effects of seminal plasma in tumor cells and endometrial tissue may thus occur via different mechanisms.

Cytokines Induced by Seminal Plasma Are Implicated in the Proliferative Effect

Several of the cytokines up-regulated by seminal plasma in vitro promote cell proliferation and/or survival. For example, GROα enhances proliferation in epithelial ovarian cancer cell lines,31 whereas IL-1β increases primary human endometrial stromal cell survival32 and suppresses the expression of the cell cycle inhibitor transcription XIII (erbB2.1); VEGF, vascular endothelial growth factor.

### Table 2 Cytokines Induced in Endometrial Tissue in Response to Seminal Plasma

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Immune/reproductive function</th>
<th>Effect in endometriosis models</th>
<th>Regulation in endometriosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>GM-CSF</td>
<td>Pro-inflammatory</td>
<td>Unknown</td>
<td>↔ In peritoneal fluid46,55</td>
</tr>
<tr>
<td></td>
<td>Postcoital leukocyte recruitment and activation (esp. DC) (reviewed41–53)</td>
<td></td>
<td>↔ In peripheral blood56,57</td>
</tr>
<tr>
<td>GRO</td>
<td>Pro-inflammatory/angiogenic/tumorigenic Neutrophil chemotaxis58</td>
<td>† Survival and malignant transformation (ovarian EC)59</td>
<td>↑ In peritoneal fluid30,61</td>
</tr>
<tr>
<td></td>
<td>Endothelial cell tube formation60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1β</td>
<td>Pro-inflammatory</td>
<td>↑ Angiogenic/pro-inflammatory factors (ie, VEGF/IL-6) (pHESC; mRNA and protein)43,49</td>
<td>↑34,46 or ↔ 65 In peritoneal fluid</td>
</tr>
<tr>
<td></td>
<td>↑ Master Th2 cytokine TSLP (thymic stromal lymphoprotein) (pHESC)65</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>↑ Apoptosis (pHEEC)</td>
<td>↓ Inhibitory mediator of cell cycle progression (Tob-1) (pHESC)43,49</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↑ Cytokines (eg, GRO, GM-CSF, IL-8, and IL-1β) (pHESC; mRNA)50</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>↑ Migration/invasion (EcMSC)</td>
<td></td>
</tr>
<tr>
<td>MDC</td>
<td>Eosinophil,66 monocyte, DC, NK cell,67 and activated T-cell68 chemotaxis Platelet activator69</td>
<td>↑ In late secretory phase [endometrial glandular epithelium (predominantly) and stromal cells; protein]40</td>
<td>↑ In peritoneal fluid73</td>
</tr>
<tr>
<td></td>
<td></td>
<td>↑ In gestation (endometrial macrophages; mRNA)112</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ND in conditioned media of pHESC or pHEEC71</td>
<td></td>
</tr>
<tr>
<td>MIP-1β</td>
<td>NK cell chemotaxis74</td>
<td>Unknown</td>
<td>↑ In ovarian and peritoneal lesions at the mRNA level77</td>
</tr>
<tr>
<td></td>
<td>↑ In endometritis (endometrium)75</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>↑ During labor (choriodecidua; mRNA and protein)76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-10</td>
<td>Anti-inflammatory</td>
<td>↓ TNF-α—induced inflammatory pathways in pHESC70</td>
<td>↑41 or ↔ 42 In peritoneal fluid</td>
</tr>
<tr>
<td></td>
<td>↓ Macrophage activation (ie, MHC Class II)78</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>↑ Tolerogenic macrophages (mouse decidua)79</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| DC, dendritic cell; EC, epithelial cell; EcMSC, ectopic mesenchymal stem cell; GR0, growth-regulated oncogene; MDC, macrophage-derived chemokine; MHC, major histocompatibility complex; MIP, macrophage inflammatory protein; ND, not detectable; NK, natural killer; pHESC, primary human endometrial stromal cell; pHEEC, primary human endometrial epithelial cell; pHESC, primary human endometrial stromal cell; TNF, tumor necrosis factor; Tob-1, transducer of erbB2.1; VEGF, vascular endothelial growth factor.

The American Journal of Pathology  ■  ajp.amjpathol.org  1419
with our previous findings in human cervix and ectocervical epithelial cells.\textsuperscript{23,24} We found a trend to up-regulation of the mRNAs encoding these proteins, indicating that increased transcription is a mechanism of up-regulation likely to have at least partly contributed to our findings. Recently, Chen et al\textsuperscript{48} examined primary human endometrial stromal and epithelial endometrial cell responses to 1\% seminal plasma for 6 hours. They found that seminal plasma significantly increased GRO and GM-CSF production in stromal and epithelial cells but that macrophage inflammatory protein 1\(\beta\) was not affected. Endometrial explants contain immune cells, in contrast to endometrial and epithelial cell cultures, and the different secreted cytokine profiles are likely to reflect this difference.

Up-regulation of IL-1\(\beta\) in response to seminal plasma is consistent with findings in endometrial epithelial cell cultures.\textsuperscript{17} In a study by Lebovic et al,\textsuperscript{49} vascular epithelial growth factor and IL-6 mRNA and protein synthesis were enhanced by IL-1\(\beta\) in ectopic endometriotic but not eutopic endometrial stromal cells. IL-1\(\beta\) also induced the expression of C-X-C motif chemokine ligands 1, 2, and 8 and CSF2\textsuperscript{50}. C-X-C motif chemokine ligand 1 and CSF2 showed trends toward increased transcript abundance in our study. A feed-forward IL-1\(\beta\) up-regulation of its own transcript was also identified.\textsuperscript{50} It is apparent that a complex network of cytokine and chemokine interactions occurs in endometrial tissues in response to seminal plasma that, as we have shown, is associated with a propensity for ectopic growth. Further work is required to tease out the relative contribution of the seminal plasma—induced cytokines to this process. The functions of the up-regulated cytokines and our current understanding of their roles in endometriosis are summarized in Table 2.

There was no significant induction of the major M2 macrophage polarizing cytokines IL-4 or macrophage CSF in endometrial explants exposed to seminal plasma, although seminal plasma itself contained significant quantities (approximately 3 ng/mL) of macrophage CSF that may have influenced macrophage phenotype. To determine whether alterations in M1:M2 macrophage activity occurred early after seminal plasma exposure and were undetectable in day-14 lesions due to resolution of the inflammatory process in both experimental groups, the activation status of macrophages was examined in endometrial tissues after exposure to seminal plasma for 24 hours in \textit{vitro}. Again, the M2 macrophage phenotype predominated in both groups, and there was no evidence that seminal plasma altered the activation status of macrophages. Therefore, this did not appear to have been the mechanism for the endometriosis-like lesion enhancement in response to seminal plasma exposure.

**Conclusion**

Seminal fluid and the postcoital inflammatory response it provokes in the reproductive tract contribute to optimal implantation and pregnancy outcomes. The current data provide proof of principle that seminal plasma can effect pathophysiological alterations in endometrial cells and tissues that, in the context of endometrial shedding during menses, may facilitate endometriotic lesion survival and development. The potential bioactive factor(s) in seminal plasma responsible for this effect include TGF-\(\beta\)1, prostat glandin E, and estradiol,\textsuperscript{39,40} but this remains to be determined. Women with pre-existing endometriosis may be particularly susceptible, as endometrial epithelial and stromal cells from women with endometriosis had an enhanced proliferative response to seminal plasma compared with that in cells from endometriosis-free women in \textit{vitro}.\textsuperscript{16} It will be important to determine whether physiological routes of seminal plasma exposure do indeed confer an increased risk for endometriosis or contribute to its development in women. If so, modifications to sexual activity may reduce this risk and potentially lower the prevalence and severity of this disease.

**Acknowledgments**

We thank Suzanne Edwards for assistance with statistical analysis and Dr. Prabath Waagarachichi for endometrial tissue collection. We also acknowledge Dr. Wendy Ingman for assistance with CCR7, iNOS, and MMR IHC staining.

**Supplemental Data**

Supplemental material for this article can be found at http://dx.doi.org/10.1016/j.ajpath.2015.01.010.

**References**

9. Sampson JA: Peritoneal endometriosis due to menstrual dissemina-
tion of endometrial tissue into the peritoneal cavity. Am J Obstet
Gynecol 1927, 14:442–446
10. Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP,
MacGregor S, Gordon SD, Henders AK, Martin NG, Attia J,
Holliday EG, McEvoy M, Scott RJ, Kennedy SH, Trelor SA,
Missmer SA, Adachi S, Tanaka K, Nakamura Y, Zondervan KT,
Zembutsu H, Montgomery GW: Genome-wide association meta-analysis
11. Pizzo A, Salmeri FM, Ardisa FV, Sofo V, Tripedi M, Marsico S:
Behaviour of cytokine levels in serum and peritoneal fluid of women
12. Llovero G, Maiorano E, Napoli A, Velasigi L, Marra E, Perlini E:
Transforming growth factor-beta 1 and insulin-like growth factor-I
expression in ovarian endometriotic cysts: a preliminary study. Int J
13. Oosterlynck DJ, Meuleman C, Waer M, Koninckx PR: Transforming
14. Hull ML, Johan MZ, Hodge WL, Robertson SA, Ingman WV: Host-
differential regulates in
18. Gardner S, Petersen S, Hobbins JC: Seminal fluid enhances adhesion
22. Vousden KH, Stinchcombe S, Zukerberg L: TGF-beta1 blocks transi-
23. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA: Seminal
24. Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K
27. World Health Organization: WHO Laboratory Manual for the ex-
2007, 13:491
fl
155
331
327x360}e
150
511
400
fl
128
209
427
377
127x191}501
235
619
fi
1359
e
121
1551
Sutherland JR, Sales KJ, Jabbour HN, Katz AA: Seminal plasma
28. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K,
Duleba AJ: Resveratrol inhibits development of experimental endo-
metriosis in vivo and reduces endometrial stromal cell invasiveness
29. Herington JL, Crispens MA, Carvalho-Macedo AC, Camargos AF,
Lebovic DI, Bruner-Tran KL, Osteen KG: Development and pre-
vention of post Surgical adhesions in a chimeric mouse model of
30. Hull ML, Escareno CR, Godsland JM, Doig JR, Johnson CM,
Phillips SC, Smith SK, Tavaré S, Print CG, Charnock-Jones DS:
Endometrial-peritoneal interactions during endometriotic lesion
31. Filer RB, Wu CH: Coitus during menses. Its effect on endometriosis
32. Hartman CG: How do sperms get into the uterus. Fertil Steril 1957, 8:
403–427
33. Egli GE, Newton M: The transport of carbon particles in the human
34. Kunz G, Leyendecker G: Uterine peristaltic activity during the
menstrual cycle: characterization, regulation, function and dysfunc-
hyperperistalsis and dysperistalsis as dysfunctions of the mechanism
of rapid sperm transport in patients with endometriosis and infertility.
Hum Reprod 1996, 11:1542–1551
The uterine peristaltic pump. Normal and impaired sperm transport
within the female genital tract. Adv Exp Med Biol 1997, 424:
267–277
37. Robertson S: Seminal plasma and male factor signalling in the female
38. Shankey DJ, Macpherson AM, Tremellen KP, Mottershead DG,
Gilchrist RB, Robertson SA: TGF-beta mediates proinflammatory
feral fluid inhibiting the growth of endo-
39. Templeton AA, Cooper I, Kelly RW: Prostaglandin concentrations in
40. Buan L, Mieusset R, Audran F, Lumbroso S, Sultan C: Increased
oestriol level in seminal plasma in infertile men. Hum Reprod 1993,
8:74–77
41. Bolitho C, Hahn MA, Baxter RC, Marsh DJ: The chemokine CXCL1
induces proliferation in epithelial ovarian cancer cells by trans-
activation of the epidermal growth factor receptor. Endocr Relat
Cancer 2010, 17:929–940
of vascular endothelial growth factor and interleukin-1beta on apoptosis
in endometrial cell cultures from patients with endometriosis and
43. Lebovic DJ, Baldocci RA, Mueller MD, Taylor RN: Altered
expression of a cell-cycle suppressor gene, TEB-1, in endometriotic
44. Beales IL: Effect of interleukin-1beta on proliferation of gastric
epithelial cells in culture. BMC Gastroenterol 2002, 2:7
45. Chegini N, Tang XM, Dou Q: The expression, activity and regulation
of granulocyte macrophage-colony stimulating factor in human
endometrial epithelial and stromal cells. Mol Hum Reprod 1999,
5:459–466
46. Hess AP, Nayak NR, Giudice LC: Oviduct and Endometrium: Cyclic
Changes in the Primate Oviduct. Edited by Neill JD. New York,
Elsevier, 2006, pp 337–382
47. Abbas AR, Baldwin D, Ma Y, Ouyang W, Gurney A, Martin F,
Fong S, van Lookeren Campagne M, Godowski P, Williams PM,
Chan AC, Clark HF: Immune response in silico (IRIS): immune-
specific genes identified from a compendium of microarray expres-
sion data. Genes Immun 2005, 6:446–450
48. Chen JC, Johnson BA, Erikson DW, Pilten TT, Barragan F, Chu S,
Kohgadai N, Irwin JC, Greene WC, Giudice LC, Roan NR: Seminal
E36–E44
26. National Health and Medical Research Council: Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes,
ed 6. Canberra, National Health and Medical Research Council, 2013
27. World Health Organization: WHO Laboratory Manual for the ex-
amination and processing of human semen. ed 5. Geneva,
Switzerland, WHO Press, 2010

The American Journal of Pathology ■ ajp.amjpathol.org
plasma induces global transcriptomic changes associated with cell migration, proliferation and viability in endometrial epithelial cells and stromal fibroblasts. Hum Reprod 2014, 29:1255–1270


70. Jones RL, Morison NB, Hannon NJ, Critchley HO, Salamonson LA: Chemokine expression is dysregulated in the endometrium of women using progestin-only contraceptives and correlates to elevated recruitment of distinct leukocyte populations. Hum Reprod 2005, 20: 2724–2734